The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a study in 107 patients
M Wallwiener, AD Hartkopf, S Riethdorf, J Nees, FA Taran, B Schönfisch, J Heil, C Sohn, K Pantel, A Trumpp, A Schneeweiss · Geburtshilfe und Frauenheilkunde · 2014 · Heft 09
Bibliografische Angaben
Zusammenfassung
Purpose: To retrospectively compare the expression of human epidermal growth factor receptor 2 (HER2) by the primary tumor, metastatic tissue, and circulating tumor cells (CTCs) and to analyze the potential impact of HER2 overexpression by CTCs on progression-free (PFS) and overall survival (OS) of patients with metastatic breast cancer (MBC). Methods: CTC-positive (≥5 CTCs/7.5 ml peripheral blood; CellSearch®, Veridex) MBC patients aged > 18 years starting a new line of systemic treatment during 03/2010 – 07/2013 were eligible for inclusion. HER2 status was determined for CTCs (immunofluorescence) and primary (…